$2.36
3.28% yesterday
Nasdaq, Jun 11, 10:00 pm CET
ISIN
US1920051067
Symbol
CDXS

Codexis, Inc. Stock price

$2.36
-0.28 10.61% 1M
-3.45 59.38% 6M
-2.41 50.52% YTD
-0.96 28.92% 1Y
-7.98 77.18% 5Y
-1.78 43.00% 10Y
-10.90 82.20% 20Y
Nasdaq, Closing price Wed, Jun 11 2025
-0.08 3.28%
ISIN
US1920051067
Symbol
CDXS
Industry

Key metrics

Market capitalization $195.51m
Enterprise Value $164.91m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 3.31
P/S ratio (TTM) P/S ratio 3.92
P/B ratio (TTM) P/B ratio 3.94
Revenue growth (TTM) Revenue growth -32.88%
Revenue (TTM) Revenue $49.82m
EBIT (operating result TTM) EBIT $-74.02m
Free Cash Flow (TTM) Free Cash Flow $-59.85m
Cash position $59.78m
EPS (TTM) EPS $-0.90
P/E forward negative
P/S forward 2.99
EV/Sales forward 2.52
Short interest 7.04%
Show more

Is Codexis, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,841 stocks worldwide.

Codexis, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Codexis, Inc. forecast:

5x Buy
71%
2x Hold
29%

Analyst Opinions

7 Analysts have issued a Codexis, Inc. forecast:

Buy
71%
Hold
29%

Financial data from Codexis, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
50 50
33% 33%
100%
- Direct Costs 14 14
8% 8%
28%
36 36
42% 42%
72%
- Selling and Administrative Expenses 54 54
6% 6%
108%
- Research and Development Expense 44 44
16% 16%
88%
-69 -69
65% 65%
-139%
- Depreciation and Amortization 4.75 4.75
280% 280%
10%
EBIT (Operating Income) EBIT -74 -74
72% 72%
-149%
Net Profit -74 -74
14% 14%
-149%

In millions USD.

Don't miss a Thing! We will send you all news about Codexis, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Codexis, Inc. Stock News

Neutral
GlobeNewsWire
21 days ago
Presentations by leading siRNA CDMOs, Bachem, Nitto Avecia, and ST Pharm, highlight performance and transferability of Codexis double-stranded RNA ligases
Neutral
GlobeNewsWire
22 days ago
REDWOOD CITY, Calif., May 21, 2025 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading provider of enzymatic solutions for efficient and scalable therapeutics manufacturing, today announced the Company will attend the Jefferies Global Healthcare Conference, being held June 3-5, 2025, in New York, New York.
Neutral
Seeking Alpha
28 days ago
Codexis, Inc. (NASDAQ:CDXS ) Q1 2025 Earnings Conference Call May 14, 2025 4:30 PM ET Company Participants Carrie McKim - Director of Investor Relations Stephen Dilly - President and Chief Executive Officer Georgia Erbez - Chief Financial Officer Stefan Lutz - Senior Vice President of Research Conference Call Participants Kristen Kluska - Cantor Fitzgerald Tycho Peterson - Jefferies Allison Bra...
More Codexis, Inc. News

Company Profile

Codexis, Inc. engages in the discovery, development, and sale of proteins. The company offers enzyme optimization services and developing biocatalyst products. The firm operates through the following segments: Performance Enzymes and Novel Biotherapeutics. Its technologies accelerate the development of manufacturing processes for active pharmaceutical ingredients fine chemicals, agrochemicals, food ingredients, detergents and biofuels. The company was founded in January 2002 and is headquartered in Redwood City, CA.

Head office United States
CEO Stephen Dilly
Employees 188
Founded 2002
Website www.codexis.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today